Central Nervous System Lymphoma Clinical Trials in New York, New York
9 recruitingNew York, New York
Showing 1–9 of 9 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled18 locationsNCT07104032
Recruiting
Phase 1
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 1
A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)
Secondary Central Nervous System LymphomaPrimary Central Nervous System (CNS) Lymphoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT07137494
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Primary Central Nervous System Lymphoma
Providence Health & Services28 enrolled7 locationsNCT06175000
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+5 more
Miltenyi Biomedicine GmbH248 enrolled25 locationsNCT04792489